PRE earnings

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced it will release financial results for the first quarter 2026 ended March 31, 2026 before market open on Thursday, May 14, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Thursday, May 14, 2026Time:8:30 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878WebcastPRE Conference Call

Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium he

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Wednesday, February 18, 2026Time:10:00 a.m. Eastern TimeDial-in:1-877-425-9470International Dial-in:1-201-389-0878

Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial

CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced it will release financial results for the third quarter 2025 ended September 30, 2025 before market open on Monday, November 10, 2025. The Company will also hold its first ever earnings conference call the same day at 8:30 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts. Date:Monday, November 10, 2025Time:8:30 a.m. Eastern TimeDial-in:1-844-425-9470International Dial-in:201-298-0878WebcastPRE Conference Call An audio replay of the webcast will

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, has engaged international investor relations specialists MZ Group ("MZ") to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Prenetics management to develop and implement a capital markets strategy designed to increase the Company's visibility throughout the investment community. The campaign will highlight how Prenetics is at the forefront of cutting-edge technological advancements in health and wellness. Under the Prenetics umbre

(Prof. Dennis Lo and Danny Yeung at Signing Ceremony) - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics which is supported by the InnoHK Initiative of the Innovation and Technology Commission of the Hong Kong SAR Government. - By 2030, the early cancer detection screening opportunity is estimated to be US$6bn in Asia on an annual basis.1 - Prof. Dennis Lo is the Li Ka Shing Professor of Medicine of the Chinese University of Hong Kong (CUHK) and the Scientific Director of the Centre for Novostics. HONG KONG, June 25, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leadi